Capstone Therapeutics (CAPS) Competitors $1.51 -0.01 (-0.66%) As of 07/3/2025 01:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesSEC FilingsTrendsBuy This Stock CAPS vs. TRVN, NMTR, PBLA, SYRS, REVB, HEPA, ATXI, VIRX, BIOR, and NCNAShould you be buying Capstone Therapeutics stock or one of its competitors? The main competitors of Capstone Therapeutics include Trevena (TRVN), 9 Meters Biopharma (NMTR), Panbela Therapeutics (PBLA), Syros Pharmaceuticals (SYRS), Revelation Biosciences (REVB), Hepion Pharmaceuticals (HEPA), Avenue Therapeutics (ATXI), Viracta Therapeutics (VIRX), Biora Therapeutics (BIOR), and NuCana (NCNA). These companies are all part of the "pharmaceutical products" industry. Capstone Therapeutics vs. Its Competitors Trevena 9 Meters Biopharma Panbela Therapeutics Syros Pharmaceuticals Revelation Biosciences Hepion Pharmaceuticals Avenue Therapeutics Viracta Therapeutics Biora Therapeutics NuCana Trevena (NASDAQ:TRVN) and Capstone Therapeutics (NASDAQ:CAPS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, profitability, institutional ownership, analyst recommendations, dividends, media sentiment and earnings. Do analysts recommend TRVN or CAPS? Trevena presently has a consensus price target of $5.00, suggesting a potential upside of 431.91%. Given Trevena's stronger consensus rating and higher probable upside, research analysts plainly believe Trevena is more favorable than Capstone Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Trevena 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Capstone Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has preferable valuation & earnings, TRVN or CAPS? Capstone Therapeutics has higher revenue and earnings than Trevena. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTrevena$443K2.03-$40.29M-$47.04-0.02Capstone Therapeutics$43.42M0.01-$2.56MN/AN/A Which has more risk & volatility, TRVN or CAPS? Trevena has a beta of 0.61, indicating that its stock price is 39% less volatile than the S&P 500. Comparatively, Capstone Therapeutics has a beta of -0.82, indicating that its stock price is 182% less volatile than the S&P 500. Is TRVN or CAPS more profitable? Company Net Margins Return on Equity Return on Assets TrevenaN/A N/A -119.55% Capstone Therapeutics N/A N/A N/A Does the media prefer TRVN or CAPS? In the previous week, Trevena and Trevena both had 1 articles in the media. Trevena's average media sentiment score of 0.00 beat Capstone Therapeutics' score of -0.33 indicating that Trevena is being referred to more favorably in the media. Company Overall Sentiment Trevena Neutral Capstone Therapeutics Neutral Do insiders and institutionals hold more shares of TRVN or CAPS? 13.6% of Trevena shares are owned by institutional investors. Comparatively, 2.5% of Capstone Therapeutics shares are owned by institutional investors. 2.7% of Trevena shares are owned by insiders. Comparatively, 42.8% of Capstone Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. SummaryTrevena beats Capstone Therapeutics on 6 of the 10 factors compared between the two stocks. Get Capstone Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CAPS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CAPS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CAPS vs. The Competition Export to ExcelMetricCapstone TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$238K$2.91B$5.56B$9.04BDividend YieldN/A2.44%5.24%4.01%P/E RatioN/A21.5627.6420.24Price / Sales0.01274.17416.55117.31Price / CashN/A42.7336.8958.10Price / Book-0.087.518.035.67Net Income-$2.56M-$55.14M$3.18B$249.21M7 Day Performance-9.58%4.61%2.93%3.28%1 Month Performance-18.82%0.90%1.72%3.95%1 Year PerformanceN/A5.40%34.39%20.98% Capstone Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CAPSCapstone TherapeuticsN/A$1.51-0.7%N/AN/A$238K$43.42M0.0038Positive NewsTRVNTrevena1.6276 of 5 stars$1.11+2.8%$5.00+350.5%-82.9%$1.06M$443K-0.0240Gap DownNMTR9 Meters BiopharmaN/AN/AN/AN/A$1.04MN/A-0.0220PBLAPanbela Therapeutics0.082 of 5 stars$0.21+3.4%N/A-56.4%$1.02MN/A0.006SYRSSyros Pharmaceuticals4.3517 of 5 stars$0.03+3.1%$3.33+11,048.3%-99.5%$802K$386K-0.01120Gap DownREVBRevelation Biosciences0.466 of 5 stars$0.76-7.4%N/A-97.3%$790KN/A-0.0110HEPAHepion Pharmaceuticals0.689 of 5 stars$0.07-6.4%N/A-99.9%$767KN/A-0.0220Gap DownATXIAvenue Therapeutics2.5598 of 5 stars$0.24-0.1%N/A-89.8%$765KN/A0.014Trending NewsVIRXViracta Therapeutics2.139 of 5 stars$0.02+11.9%$1.75+9,731.5%-96.6%$707KN/A-0.0220BIORBiora TherapeuticsN/A$0.15+6.5%$23.00+15,664.2%-97.8%$660K$892K-0.01120Gap UpNCNANuCana2.5195 of 5 stars$0.09+4.0%$25.00+29,003.6%-98.0%$500KN/A-0.0130Gap Down Related Companies and Tools Related Companies TRVN Alternatives NMTR Alternatives PBLA Alternatives SYRS Alternatives REVB Alternatives HEPA Alternatives ATXI Alternatives VIRX Alternatives BIOR Alternatives NCNA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CAPS) was last updated on 7/6/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored140% Yields From Stocks Like Tesla? Here's How (July 4th Special)Imagine getting a 140% dividend from your investments. Even better? It works with big names like Tesla, ...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.The robotics revolution is here. And it's set to impact everything from how we manufacture goods to how we ...Weiss Ratings | SponsoredTrump's ticking time bombA looming tariff deadline on July 9th could be the spark — but what’s buried inside a recent White House docum...Porter & Company | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Capstone Therapeutics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Capstone Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
